Targeted 1:1 meetings promises knowledge gain and new business contacts
Building on the experience of the EU Task Force for Industrial Scale-up of COVID-19 vaccines and therapeutics, the European Commission continues to facilitate cooperation between actors in the EU supply chain to ensure that available therapeutics are produced in sufficient quantity as soon as possible.
On the 29 and 30 November, the European Commission is organising the Second Virtual Matchmaking Event on COVID-19 Therapeutics in partnership with the Council of European BioRegions (CEBR), the European Cluster Alliance (ECA) and the ECCP.
This event will aim to accelerate:
- The development of new and repurposed medicines for COVID-19 therapeutics
- The development of medicines used to treat the symptoms of COVID-19
- The production of disposable materials (e.g. single use systems), ingredients and raw materials required for the manufacture of medicinal products
It will also aim to mobilise the EU pharma manufacturing capacity for the production of medicines to treat and prevent COVID-19.
The target group is the entire EU COVID-19 therapeutics supply chain that has development or production facilities in the EU, such as clinical research organisations, treatment developers, funding providers and manufacturing suppliers. In their applications, companies must be specific on the technology they use and on how their capacities are relevant for the purpose of this event.
Companies will only be formally registered for the event if the criteria detailed in the event’s Call for Expression of Interest is met.
Companies interested in participating in the event must complete the event’s registration form by 18 November 2021.
Any questions can be addressed to Daniela Coutinho and Raquel Gonçalves, from the European Cluster Collaboration Platform at email@example.com